JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

Search

Intuitive Surgical Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

476.28 1.34

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

469.77

Max

475.46

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-45M

658M

Pardavimai

187M

2.4B

P/E

Sektoriaus vid.

67.603

34.393

Pelnas, tenkantis vienai akcijai

1.81

Pelno marža

26.984

Darbuotojai

15,638

EBITDA

268M

987M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+28.25% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-10-16

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-12B

173B

Ankstesnė atidarymo kaina

474.94

Ankstesnė uždarymo kaina

476.28

Naujienos nuotaikos

By Acuity

10%

90%

5 / 374 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bearish Evidence

Intuitive Surgical Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-07-22 21:13; UTC

Uždarbis

Intuitive Surgical Logs Higher Profit, Revenue in 2Q

2025-04-22 20:55; UTC

Uždarbis

Intuitive Surgical Reports Higher 1Q Profit, Warns of Tariff Hit to Margins

2025-01-23 21:41; UTC

Uždarbis

Intuitive Surgical Posts Higher 4Q Profit, Revenue on Continued Procedure Growth

2025-01-21 18:37; UTC

Įsigijimai, susijungimai, perėmimai

Intuitive to Establish Direct Presence in Europe With Acquisition

2025-07-22 20:14; UTC

Uždarbis

Intuitive Surgical Sees FY25 Non-GAAP Gross Profit Margin to Be Within Range of 66% and 67% >ISRG

2025-07-22 20:13; UTC

Uždarbis

Intuitive Surgical Sees FY25 Worldwide Da Vinci Procedure Growth of 15.5% to 17% >ISRG

2025-07-22 20:13; UTC

Uždarbis

Intuitive Surgical Grew Da Vinci Surgical System Installed Base to 10,488 Systems as of June 30 >ISRG

2025-07-22 20:05; UTC

Uždarbis

Intuitive Surgical 2Q Net $658.4M >ISRG

2025-07-22 20:05; UTC

Uždarbis

Intuitive Surgical 2Q Da Vinci Surgical Systems Shipped 395.00 >ISRG

2025-07-22 20:05; UTC

Uždarbis

Intuitive Surgical 2Q Rev $2.44B >ISRG

2025-07-22 20:05; UTC

Uždarbis

Intuitive Surgical 2Q Adj EPS $2.19 >ISRG

2025-07-22 20:05; UTC

Uždarbis

Intuitive Surgical 2Q EPS $1.81 >ISRG

2025-04-22 20:13; UTC

Uždarbis

Intuitive Surgical Sees FY25 Worldwide Da Vinci Procedure Growth of 15% to 17%

2025-04-22 20:05; UTC

Uždarbis

Intuitive Surgical 1Q EPS $1.92 >ISRG

2025-04-22 20:05; UTC

Uždarbis

Intuitive Surgical 1Q Adj EPS $1.81 >ISRG

2025-04-22 20:05; UTC

Uždarbis

Intuitive Surgical 1Q Net $698.4M >ISRG

2025-04-22 20:05; UTC

Uždarbis

Intuitive Surgical 1Q Da Vinci Surgical Systems Shipped 367.00 >ISRG

2025-04-22 20:05; UTC

Uždarbis

Intuitive Surgical 1Q Rev $2.25B >ISRG

2025-01-24 21:17; UTC

Uždarbis

Why Intuitive Surgical Crumbled Despite Its Upbeat Fourth-Quarter Report -- IBD

2025-01-24 18:18; UTC

Uždarbis

Intuitive Surgical Stock Drops After Earnings Beat. Wall Street Is Still Optimistic. -- Barrons.com

2025-01-24 13:11; UTC

Svarbiausios naujienos

Dow Jones Futures Fall Ahead Of Inflation Data; 5 Tech Giants To Buy And Watch -- IBD

2025-01-24 09:51; UTC

Karštos akcijos

Stocks to Watch Friday: Texas Instruments, CSX, Burberry, American Express -- WSJ

2025-01-23 21:10; UTC

Uždarbis

Intuitive Surgical Expects Non-GAAP Gross Profit Margin to Be Within 67% and 68% of Net Rev in 2025 >ISRG

2025-01-23 21:09; UTC

Uždarbis

Intuitive Surgical Expects Worldwide Da Vinci Procedures to Increase 13% to 16% in 2025 >ISRG

2025-01-23 21:09; UTC

Uždarbis

Intuitive Surgical Grew Da Vinci Surgical System Installed Base to 9,902 Systems as of Dec 31 >ISRG

2025-01-23 21:05; UTC

Uždarbis

Intuitive Surgical 4Q Adj EPS $2.21 >ISRG

2025-01-23 21:05; UTC

Uždarbis

Intuitive Surgical 4Q Da Vinci Surgical Systems Shipped 493.00 >ISRG

2025-01-23 21:05; UTC

Uždarbis

Intuitive Surgical 4Q Rev $2.41B >ISRG

2025-01-23 21:05; UTC

Uždarbis

Intuitive Surgical 4Q Net $685.7M >ISRG

2025-01-23 21:05; UTC

Uždarbis

Intuitive Surgical 4Q EPS $1.88 >ISRG

Akcijų palyginimas

Kainos pokytis

Intuitive Surgical Inc Prognozė

Kainos tikslas

By TipRanks

28.25% į viršų

12 mėnesių prognozė

Vidutinis 602.89 USD  28.25%

Aukščiausias 685 USD

Žemiausias 440 USD

Remiantis 22 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Intuitive Surgical Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

22 ratings

17

Pirkti

4

Laikyti

1

Parduoti

Techninis įvertinimas

By Trading Central

514.59 / 539.05Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Weak Bearish Evidence

Vidutinės trukmės periodas

Weak Bullish Evidence

Ilgalaikis periodas

Strong Bullish Evidence

Rinkos nuotaikos

By Acuity

5 / 374 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Labai stiprus bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Intuitive Surgical Inc

Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung. It also provides a suite of stapling, energy, and core instrumentation for its multi-port da Vinci surgical systems; progressive learning pathways to support the use of its technology; infrastructure of service and support specialists, a complement of services to its customers, including installation, repair, maintenance, 24/7 technical support, and proactive system health monitoring; and integrated digital capabilities providing connected offerings, streamlining performance for hospitals with program-enhancing insights. The company sells its products through direct sales organizations, such as capital and clinical sales teams. It has a collaboration agreement with FluoGuide A/S for head & neck cancer. The company was incorporated in 1995 and is headquartered in Sunnyvale, California.